Comparison of the cost-effectiveness for basal-bolus therapy of type-1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens in the Netherlands

被引：0
|
作者：
Valentine, WJ
Wittrup-Jensen, K
Palmer, AJ
Roze, S
机构：
[1] CORE Ctr Outcomes Res, Basel, Switzerland
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：255 / 255
页数：1
相关论文
共 50 条
  • [41] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes
    Hirsch, I.
    Franek, E.
    Courreges, J. P.
    Mersebach, H.
    Dykiel, P.
    Bode, B. W.
    [J]. DIABETOLOGIA, 2011, 54 : S427 - S427
  • [42] Distinct pharmacodynamics of insulin glargine and insulin detemir: Crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen
    Kato, Tomoko
    Tokubuchi, Ichiro
    Muraishi, Kazuhisa
    Sato, Shuichi
    Kato, Tamotsu
    Hara, Kento
    Tanaka, Kayo
    Kaku, Hiroo
    Tajiri, Yuji
    Yamada, Kentaro
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (03) : E64 - E66
  • [43] Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
    Abe, Shinya
    Inoue, Gaku
    Yamada, Satoru
    Irie, Junichiro
    Nojima, Hiroyuki
    Tsuyusaki, Kaoru
    Usui, Kensuke
    Atsuda, Koichiro
    Yamanouchi, Toshikazu
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2011, 4 : 283 - 288
  • [44] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [45] Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes
    Chen, J. -W.
    Lauritzen, T.
    Bojesen, A.
    Christiansen, J. S.
    [J]. DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 682 - 689
  • [46] RAPID-ACTING INSULIN ANALOGUES IN BASAL-BOLUS REGIMENS IN TYPE 1 DIABETES MELLITUS
    Garg, Satish
    Javier Ampudia-Blasco, Francisco
    Pfohl, Martin
    [J]. ENDOCRINE PRACTICE, 2010, 16 (03) : 486 - 505
  • [47] Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine
    Bode, B
    Hirsch, I
    Hu, P
    Santiago, O
    [J]. DIABETES, 2003, 52 : A102 - A102
  • [48] Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
    Le Floch, Jean-Pierre
    Levy, Marc
    Mosnier-Pudar, Helen
    Nobels, Frank
    Laroche, Sylvie
    Gonbert, Sophie
    Eschwege, Eveline
    Fontaine, Pierre
    [J]. DIABETES CARE, 2009, 32 (01) : 32 - 37
  • [49] Quality of life (QoL) assessment of insulin detemir and NPH human insulin in Japanese subjects with diabetes on basal-bolus regimen
    Ishii, Hitoshi
    Iwamoto, Yasuhiko
    Kaku, Kohei
    Kawamori, Ryuzo
    Tajima, Naoko
    Kobayashi, Masashi
    [J]. DIABETES, 2007, 56 : A710 - A710
  • [50] An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Lawson, Jack
    Chubb, Barrie
    Gorst-Rasmussen, Anders
    Evans, Lyndon Marc
    [J]. DIABETES THERAPY, 2023, 14 (01) : 123 - 137
12345